Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Gilead Sciences experiences growth in 2010

Gilead Sciences experiences growth in 2010

27th January 2011

Gilead Sciences has published its financial report for 2010, a year which saw a double-digit percentage increase in the company's annual sales.

The pharmaceutical manufacturer's product sales for the year generated $7.39 billion (4.65 billion pounds), up by 14 percent compared to 2009, while total revenues rose by 13 percent.

Drugs which saw increased sales during 2010 include antiviral agents such as Atripla, Viread and Truvada, with other key products including Ranexa and Letairis also experiencing rising demand.

In addition, the firm was able to produce positive phase III data on newer treatments such as Cayston, while closing a deal to purchase Arresto Biosciences.

It also announced the authorisation of a new three-year stock repurchase programme that will commence when the existing scheme finishes in May 2011.

Other treatments currently in development at Gilead include the HIV therapy regimen Quad, which combines Truvada with two other active ingredients in a single tablet.ADNFCR-8000103-ID-800368012-ADNFCR

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.